Combining Anti-VEGF Approaches with Oxaliplatin in Advanced Colorectal Cancer

American Cancer Society, 2004 August, 1984, Clinical perspective of human colorectal cancer metastases, Cancer Metastasis Rev, 3, 303, 10.1007/BF00051457 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Reinmuth, 2003, Biology of angiogenesis in tumors of the gastrointestinal tract, Microsc Res Tech, 60, 199, 10.1002/jemt.10258 Tsuchida, 1999, Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer, Int J Oncol, 14, 47 Rosen, 2000, Antiangiogenic strategies and agents in clinical trials, Oncologist, 5, 20, 10.1634/theoncologist.5-suppl_1-20 Takahashi, 1997, Vessel counts and expression of vascular endothelial growth factor as prognostic factors in nodenegative colon cancer, Arch Surg, 132, 541, 10.1001/archsurg.1997.01430290087018 Takahashi, 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, 55, 3964 Carmeliet, 1996, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 380, 435, 10.1038/380435a0 Ferrara, 1996, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 380, 439, 10.1038/380439a0 Benjamin, 1999, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal, J Clin Invest, 103, 159, 10.1172/JCI5028 Teicher, 1992, Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease, Cancer Res, 52, 6702 Senger, 1993, Vascular permeability factor (VPE, VEGF) in tumor biology, Cancer Metastasis Rev, 12, 303, 10.1007/BF00665960 Dvorak, 1992, Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation, Ann N Y Acad Sci, 667, 101, 10.1111/j.1749-6632.1992.tb51603.x Fidler, 2001, Biology of cancer: angiogenesis, 137 Mendel, 2000, Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent, Anticancer Drug Des, 15, 29 Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088 Hlatky, 2002, Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us, J Natl Cancer Inst, 94, 883, 10.1093/jnci/94.12.883 Weidner, 1991, Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma, N Engl J Med, 324, 1, 10.1056/NEJM199101033240101 Obermair, 1997, Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival, Int J Cancer, 74, 455, 10.1002/(SICI)1097-0215(19970822)74:4<455::AID-IJC17>3.0.CO;2-8 Uzzan, 2004, Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis, Cancer Res, 64, 2941, 10.1158/0008-5472.CAN-03-1957 Catalano, 2003, Increased vascular endothelial growth factor (VEGF) serum levels correlate with poor outcome in advanced colorectal cancer (CRC) patients, Proc Am Soc Clin Oncol, 22, 876 Padhani, 2001, Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies, Clin Radiol, 56, 607, 10.1053/crad.2001.0762 Gupta, 2002, PET for in vivo pharmacokinetic and pharmacodynamic measurements, Eur J Cancer, 38, 2094, 10.1016/S0959-8049(02)00413-6 Morgan, 2003, J Clin Oncol, 21, 3955, 10.1200/JCO.2003.08.092 Ellis, 2003, Antiangiogenic therapy: more promise and, yet again, more questions, J Clin Oncol, 21, 3897, 10.1200/JCO.2003.07.977 Balzer, 2000, Oxaliplatin: a platinum compound for colorectal cancer, Cancer Pract, 8, 201, 10.1046/j.1523-5394.2000.84005.x Wilson, 2002, Acute oxaliplatin-induced peripheral nerve hyperexcitability, J Clin Oncol, 20, 1767, 10.1200/JCO.2002.07.056 Raymond, 1998, Oxaliplatin: a review of preclinical and clinical studies, Ann Oncol, 9, 1053, 10.1023/A:1008213732429 Wiseman, 1999, Oxaliplatin: a review of its use in the management of metastatic colorectal cancer, Drugs Aging, 14, 459, 10.2165/00002512-199914060-00006 Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 52, 4593 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Hurwitz Hurwitz H, Fehrenbacher L Hainsworth J, et al. Bevacizumab in combination with 5-fluorouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer. Presented at: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #286. Mass, 2004, Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: a combined analysis, Proc Am Soc Clin Oncol, 23, 274 2004 Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988 Bold, 2000, New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis, J Med Chem, 42, 2310, 10.1021/jm9909443 Drevs, 2003, Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases, Proc Am Soc Clin Oncol, 22, 284 Yung, 2003, A phase I trial of singleagent PTK787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme, Proc Am Soc Clin Oncol, 22, 99 Trarbach, 2003, Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 22, 285 Steward, 2003, Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK 787/ZK222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first-line treatment for metastatic colorectal cancer, Proc Am Soc Clin Oncol, 22, 274 Steward, 2004, Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 23, 259 Benson, 2003, Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (adv CRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200, Proc Am Soc Clin Oncol, 22, 243 Giantonio BJ, Catalano PJ, Meropol NJ, et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #241.